Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
LLY · NYSE · Pharmaceutical Preparations
Fundamental quality
95
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
On average over recent years, earnings per share grew 54.2% a year and revenue advanced 33.1% a year.
On profitability, Eli Lilly & Co shows a net margin of 35%, an ROE of 81%.
Adding up growth, profitability and financial strength, the traffic light gives LLY a fundamental quality of 95 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Eli Lilly & Co cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →